首页|伏诺拉生用于幽门螺杆菌根除治疗的临床疗效评价

伏诺拉生用于幽门螺杆菌根除治疗的临床疗效评价

扫码查看
目的 优化幽门螺杆菌(HP)根除治疗的用药方案。方法 选取 2020 年 1 月至 2022 年 12 月在医院体检中心或门诊发现感染HP且胃镜检查无溃疡及其他胃黏膜病变的患者 312 例,根据根除方案用药的不同分为质子泵抑制剂(PPI)四联组(124 例)、伏诺拉生(VPZ)四联组(84 例)、VPZ二联组(97 例)。PPI四联组予艾司奥美拉唑肠溶胶囊[每次 20 mg、每日 2 次(bid)]+阿莫西林胶囊(每次 1 g、bid)+克拉霉素缓释胶囊(每次 500 mg、bid)+胶体果胶铋胶囊[每次 200 mg、每日 3 次(tid)];VPZ四联组予富马酸伏诺拉生片(每次 20 mg、bid)+阿莫西林胶囊(每次 1 g、bid)+克拉霉素缓释胶囊(每次 500 mg、bid)+胶体果胶铋胶囊(每次 200 mg、tid);VPZ二联组予富马酸伏诺拉生片(每次 20 mg、bid)+阿莫西林胶囊(每次 1 g、tid)。3 组均为口服给药,疗程均为 14 d。结果 PPI四联组、VPZ四联组及VPZ二联组HP根除成功率分别为 85。48%,90。48%,88。66%,组间比较无显著差异(P>0。05),且仅VPZ四联组根除效果满意(根除率>90%);不良事件发生率分别为 15。32%,16。67%,7。72%,组间比较有显著差异(P<0。05)。结论 在无溃疡及胃黏膜病变人群的HP根除治疗中,含VPZ四联疗法的根除成功率及不良事件发生率均稍高于传统的含PPI四联疗法;VZP(联合高剂量阿莫西林)二联疗法HP根除成功率虽略高于PPI四联疗法,但仍欠满意。未来还需更多临床研究优化,以获得更理想的根除效果。
Evaluation of Clinical Efficacy of Vonoprazan in the Radical Treatment of Helicobacter Pylori
Objective To optimize the medication regimen for radical treatment of Helicobacter pylori(HP).Methods A total of 312 patients diagnosed with HP in hospital physical examination center or outpatient and without ulcer or other gastric mucosal lesion confirmed by gastroscopy from January 2020 to December 2022 were selected.They were divided into the proton pump inhibitor(PPI)-based quadruple therapy group(124 cases),vonoprazan(VPZ)-based quadruple therapy group(84 cases)and VPZ-based dual therapy group(97 cases)based on different eradication regimens.The patients in the PPI-based quadruple therapy group were given Esomeprazole Enteric Capsules[20 mg each time,twice a day(bid)]+Amoxicillin Capsules(1 g each time,bid)+Clarithromycin Sustained Release Capsules(500 mg each time,bid)+Colloidal Bismuth Pectin Capsules[200 mg each time,three times a day(tid)].The patients in the VPZ-based quadruple therapy group were given Vonoprazan Fumarate Tablets(20 mg each time,bid)+Amoxicillin Capsules(1 g each time,bid)+Clarithromycin Sustained Release Capsules(500 mg each time,bid)+Colloidal Bismuth Pectin Capsules(200 mg each time,tid).The patients in the VPZ-based dual therapy group were given Vonoprazan Fumarate Tablets(20 mg each time,bid)+Amoxicillin Capsules(1 g each time,tid).All three groups were treated orally with a course of 14 d.Results The success rates of HP eradication in the PPI-based quadruple therapy group,VPZ-based quadruple therapy group and VPZ-based dual therapy group were 85.48%,90.48%,88.66%respectively,with no significant difference among the groups(P>0.05),and only the VPZ-based quadruple therapy group had a satisfactory eradication effect(eradication rate>90%).The incidence rates of adverse events in the above three groups were 15.32%,16.67%,7.72%respectively,with significant differences among the groups(P<0.05).Conclusion In the radical treatment of HP in the population without ulcer or gastric mucosal lesion,the success rate of HP eradication and incidence of adverse events of VPZ-based quadruple therapy are slightly higher than those of traditional PPI-based quadruple therapy.Although the success rate of HP eradication of VPZ-based dual therapy(containing high-dose amoxicillin)is slightly higher than that of PPI-based quadruple therapy,it is still unsatisfactory.More clinical researches are needed in the future to achieve more ideal eradication effects.

Helicobacter pylorieradication ratevonoprazanclinical efficacy

孟雅洁、李仁冬、丁杰雯、闵枫、杜芸、王敏

展开 >

重庆市南川区人民医院,重庆 408400

幽门螺杆菌 根除率 伏诺拉生 临床疗效

重庆市卫生健康委医学科研项目

2022WSJK080

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(12)